In This Article:
In the current global market landscape, small-cap stocks have experienced a mixed performance, with the Russell 2000 index showing a decline amidst broader market volatility influenced by political changes and economic indicators. As investors navigate these uncertain times, identifying undervalued small-cap companies with insider buying can signal potential opportunities for growth, as such actions often reflect confidence from those closest to the company in its future prospects.
Top 10 Undervalued Small Caps With Insider Buying
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Sagicor Financial | 1.2x | 0.3x | 35.19% | ★★★★★★ |
Paradeep Phosphates | 23.6x | 0.8x | 29.71% | ★★★★★☆ |
PSC | 7.5x | 0.4x | 43.98% | ★★★★☆☆ |
Avia Avian | 16.6x | 3.8x | 9.50% | ★★★★☆☆ |
Trican Well Service | 8.3x | 1.0x | 14.87% | ★★★★☆☆ |
Rogers Sugar | 15.6x | 0.6x | 47.45% | ★★★★☆☆ |
NCL Industries | 14.8x | 0.5x | -81.34% | ★★★☆☆☆ |
Semen Indonesia (Persero) | 20.8x | 0.7x | 29.48% | ★★★☆☆☆ |
L.G. Balakrishnan & Bros | 13.7x | 1.6x | -36.57% | ★★★☆☆☆ |
Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
We'll examine a selection from our screener results.
Xvivo Perfusion
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Xvivo Perfusion specializes in developing and providing advanced medical technologies for organ transplantation, with a market cap of approximately SEK 6.48 billion.
Operations: Xvivo Perfusion generates revenue primarily from its Thoracic, Abdominal, and Services segments. The company has experienced fluctuations in its net income margin, with a notable increase to 27.21% by September 2024. Operating expenses have consistently been a significant component of the cost structure, driven by sales and marketing as well as research and development activities.
PE: 68.9x
Xvivo Perfusion, a player in the medical technology sector, showcases promising growth with earnings projected to rise by 24.61% annually. Recent financials highlight significant improvement; third-quarter sales reached SEK 198 million, up from SEK 147 million last year, and net income soared to SEK 86 million from just SEK 2 million. Despite relying entirely on external borrowing for funding, insider confidence is evident through recent purchases. The appointment of Lena Hagman as deputy CEO adds strategic depth to its leadership team.
-
Dive into the specifics of Xvivo Perfusion here with our thorough valuation report.
-
Review our historical performance report to gain insights into Xvivo Perfusion's's past performance.
Cutia Therapeutics
Simply Wall St Value Rating: ★★★★☆☆
Overview: Cutia Therapeutics is a company focused on developing innovative and comprehensive solutions, with operations contributing to a market capitalization of CN¥3.45 billion.